462 related articles for article (PubMed ID: 35069993)
1. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.
Mazza S; Soro S; Verga MC; Elvo B; Ferretti F; Cereatti F; Drago A; Grassia R
World J Hepatol; 2021 Dec; 13(12):1828-1849. PubMed ID: 35069993
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.
Rojas-Feria M; Castro M; Suárez E; Ampuero J; Romero-Gómez M
World J Gastroenterol; 2013 Nov; 19(42):7327-40. PubMed ID: 24259964
[TBL] [Abstract][Full Text] [Related]
3. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.
Fousekis FS; Theopistos VI; Katsanos KH; Tsianos EV; Christodoulou DK
Gastroenterology Res; 2018 Apr; 11(2):83-94. PubMed ID: 29707074
[TBL] [Abstract][Full Text] [Related]
4. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.
Navaneethan U; Shen B
Inflamm Bowel Dis; 2010 Sep; 16(9):1598-619. PubMed ID: 20198712
[TBL] [Abstract][Full Text] [Related]
5. Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.
Silva J; Brito BS; Silva INN; Nóbrega VG; da Silva MCSM; Gomes HDN; Fortes FM; Pimentel AM; Mota J; Almeida N; Surlo VC; Lyra A; Rocha R; Santana GO
Biomed Res Int; 2019; 2019():7604939. PubMed ID: 30834274
[TBL] [Abstract][Full Text] [Related]
6. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks.
Massironi S; Pirola L; Mulinacci G; Ciaccio A; Viganò C; Palermo A; Zilli A; Invernizzi P; Danese S
Inflamm Bowel Dis; 2023 Sep; 29(9):1477-1487. PubMed ID: 36040402
[TBL] [Abstract][Full Text] [Related]
7. Liver manifestations and complications in inflammatory bowel disease: A review.
Gaspar R; Branco CC; Macedo G
World J Hepatol; 2021 Dec; 13(12):1956-1967. PubMed ID: 35070000
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood.
Maggiore G; Riva S; Sciveres M
Minerva Gastroenterol Dietol; 2009 Mar; 55(1):53-70. PubMed ID: 19212308
[TBL] [Abstract][Full Text] [Related]
9. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.
Saich R; Chapman R
World J Gastroenterol; 2008 Jan; 14(3):331-7. PubMed ID: 18200656
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN.
Catassi G; D'Arcangelo G; Norsa L; Bramuzzo M; Hojsak I; Kolho KL; Romano C; Gasparetto M; Di Giorgio A; Hussey S; Yerushalmy-Feler A; Turner D; Matar M; Weiss B; Karoliny A; Alvisi P; Tzivinikos C; Aloi M
Inflamm Bowel Dis; 2023 Sep; ():. PubMed ID: 37768032
[TBL] [Abstract][Full Text] [Related]
11. Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India.
Singh A; Midha V; Narang V; Kedia S; Mahajan R; Dhoble P; Kahlon BK; Dhaliwal AS; Tripathi A; Kalra S; Jain NP; Bansal N; Banerjee R; Desai D; Dutta U; Ahuja V; Sood A
Intest Res; 2023 Oct; 21(4):452-459. PubMed ID: 36453008
[TBL] [Abstract][Full Text] [Related]
12. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
Rocha HC; Vilela EG
Gastroenterol Hepatol; 2022 Feb; 45(2):83-90. PubMed ID: 34023469
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
[TBL] [Abstract][Full Text] [Related]
14. Hepatic manifestations of inflammatory bowel diseases.
Restellini S; Chazouillères O; Frossard JL
Liver Int; 2017 Apr; 37(4):475-489. PubMed ID: 27712010
[TBL] [Abstract][Full Text] [Related]
15. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
16. Hepatopancreatobiliary manifestations of inflammatory bowel disease.
Nakamura K; Ito T; Kotoh K; Ihara E; Ogino H; Iwasa T; Tanaka Y; Iboshi Y; Takayanagi R
Clin J Gastroenterol; 2012 Feb; 5(1):1-8. PubMed ID: 26181867
[TBL] [Abstract][Full Text] [Related]
17. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
Fevery J; Van Steenbergen W; Van Pelt J; Laleman W; Hoffman I; Geboes K; Vermeire S; Nevens F
Aliment Pharmacol Ther; 2016 Mar; 43(5):612-20. PubMed ID: 26748470
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary manifestations of inflammatory bowel disease.
Yarur AJ; Czul F; Levy C
Inflamm Bowel Dis; 2014 Sep; 20(9):1655-67. PubMed ID: 24874461
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease.
Azzam N; AlRuthia Y; Alharbi O; Aljebreen A; Almadi M; Loftus EV
Hepatol Int; 2020 Dec; 14(6):1114-1124. PubMed ID: 33369708
[TBL] [Abstract][Full Text] [Related]
20. Hepatobiliary manifestations in children with inflammatory bowel disease: A single-center experience in a low/middle income country.
El-Shabrawi MH; Tarek S; Abou-Zekri M; Meshaal S; Enayet A; Mogahed EA
World J Gastrointest Pharmacol Ther; 2020 Aug; 11(3):48-58. PubMed ID: 32844043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
